On March 12, 2025, the inaugural shipment ceremony for Sintetol (generic name:Siltartoxatug Injection), an innovative, first-in-class recombinant anti-tetanus toxin monoclonal antibody drug, was grandly held at the production facility of Zhuhai Trinomab Pharmaceutical Co., Ltd.
The first shipment of Sintetol is on its ways to clinics and patients within just one month after regulatory approval with tremendous joint effort by Trinomab’s production and commercial teams. This milestone marks a breakthrough in tetanus prevention and treatment, offering a novel emergency prophylactic "weapon" for clinical use. Doctors in emergency care now have better option to offer patients with a safer and more effective drug for tetanus prevention.
Nurturing New Growth, Launching a New Journey
Government leaders from Zhuhai, Professor Liang Zijing of Guangzhou Medical University's First Affiliated Hospital, Xiang Tiemei (General Manager of Shanghai Pharma Holdings Guangdong), Chang Libo (Deputy Editor-in-Chief of Zhuhai Media Group), Wang Cheng (General Manager of Jinhang Group), Li Gang (Trinomab’s Head of Production), Zhao Wengui (Head of Greater China Commercial Operations), and representatives from Trinomab's strategic partners and employees witnessed this historic moment.
Zhao Wengui: Driving Innovation to Meet Clinical Needs
Zhao Wengui, Vice President and Head of Greater China Commercial Operations, Trinomab, made welcome remarks to attendees and reviewed the journey on the development of Sintetol. Sintetol embodies the mission to address unmet clinical needs in tetanus prevention. Compared to the existing treatments, Sintetol boasts four key advantages: safety, efficacy, stability and accessibility in production and supply.
Sintetol resolves two critical challenges in tetanus prevention:
1. Traditional horse serum products require skin tests and carry high allergy risks. Desensitization protocols involve multiple injections when skin test positive and 30-minute post-dose observation, wasting medical resources and causing patient distress.
2. Severe trauma patients demand rapid intervention in emergency care. Current tetanus shots take two days to reach peak protection levels, whereas Sintetol achieves the protective antibody levels in 95.4% of patients within12 hours [1], offering faster action and longer-lasting protection.
Zhao emphasized plans to collaborate with leading distributors like Shanghai Pharma, Sinopharm, and CR Healthcare to optimize logistics and expand hospital coverage. “We will implement targeted promotion, academic exchanges, and efficient supply chains to ensure the drug rapidily reaching to clinics and doctors, alleviating anxiety for clinicians as well as patients and patients’families,” he stated.
Professor Liang Zijing: Clinical Advantages and Call for Adoption
As the lead investigator of Phase III trial for Sintetol, Professor Liang highlighted Sintetol is a Category 1 new drug developed by Trinomab. As an upgraded "tetanus shot," it is indicated for emergency tetanus prophylaxis in adults via intramuscular injection. The drug achieves protective levels of anti-tetanus antibodies, outperforming the standard 250 IU HTIG in both efficacy and rapid-onset as well as duration of protective antibody levels in serum with a single dose, eliminating the need for skin testing, post-dose observation (for outpatient cases), or adjustments based on body weight or wound size.
He urged to accelerate Sintetol getting into more and more medical institutions and promote public education to raise awareness on progress made in tetanus prevention. “Sintetol represents a China contribution to global tetanus prevention, advancing standardized care worldwide,” he declared.
Li Gang: Ensuring Quality and Scalability
Trinomab’s production head, Li Gang, underscored Sintetol’s manufacturing excellence. The company adheres to stringent quality standards, minimizes batch variability, and leverages advanced cell culture systems, automated filling, and packaging under GMP standard to meet urgent clinical demands. “We commit to zero tolerance for defects and robust supply chains,” he pledged.
Media and Industry Perspectives: Value and Vision
Media and commercial leaders and recognize and admire contribution and significance in tetanus prevention by Sintetol. Chang Libo noted, “This shipment showcases Zhuhai’s biopharma innovation and the raise of Chinese biotech companies in the world.” Xiang Tiemei confirmed the first delivery of Sintetol to the Zhuhai People’s Hospital, emphasizing its role in “closing the last mile” for emergency care.
A New Chapter in Global Health
Witnessed by government, academic, and media leaders in the presence, Sintetol’s inaugural shipment marked Trinomab’s transition from R&D to commercialization. By bridging production to clinical practice, Sintetol opens a new era in tetanus prevention.
[1] Data from Sintetol clinical trials.
(Sintetol Trademark Registration Number: 74174546)
